Ophthalmology

Researchers from the University of Barcelona are looking to unlock the function of genes in order to design therapies to treat patients diagnosed with retinitis pigmentosa.

The theme calls on employers, insurers, and policy makers to consider how they can contribute to improved access to vision and eye health care.

With a robust pipeline, new hope for Stargardt disease and retinitis pigmentosa may be on the horizon.

The AI retinal scanning model will be free to use for all institutions.

According to the company, the clinical study update suggests continued positive trends in best-corrected visual acuity and multi-luminance mobility testing as well as positive trends in low-luminance visual acuity among treated eyes.

A panel of esteemed retina specialists recently delved into innovative therapies for neovascular age-related macular degeneration and diabetic macular edema, focusing on personalized treatment, telemedicine, and the ongoing quest for advancements.

The Ophthalmic World Leaders (OWL) Leadership Summit, scheduled for September 21 and 22, 2023, in Austin, Texas, will feature a lineup of prominent speakers and engaging discussions on a wide range of leadership topics and industry insights.

Alex Gorsky currently sits on the boards of Apple, IBM, JPMorgan Chase, and the Travis Manion Foundation, as well as the Wharton School of the University of Pennsylvania Board of Advisors.

Walgreens Boots Allianc Inc. and CVS Health are among the companies the FDA sent letters to for violating federal law.

The company is expanding its patent portfolio to 10 granted patents and 32 pending patent applications.

According to the company, OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies.

According to the companies, the collaboration has the potential to benefit patients who have suffered from specific, chronic ocular diseases.

Ocular Therapeutic, Rezolute, and Opthea will all present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City in September.

The beauty brand announces Ashley Brissette, MD, MSc, FRCSC, will be the brand's first guiding ophthalmologist.

DMEI is 1 of only 17 centers in the US certified to provide this specialized treatment. Previously, patients in the region who qualified for LUXTURNA would have had to travel to other states to receive treatment.

According to the company, NFS-05, utilizes a gene therapy approach that delivers an AAV vector containing the OPA1 gene into the vitreous cavity.

The 6-month-old boy’s dark brown eyes turned deep blue after he was treated for COVID with favipiravir.

EyeSouth Partners has partnered with Retina and Vitreous of Texas, a retina-only practice in Houston, Texas. The company’s current network encompasses 38 practices and over 300 doctors who deliver medical and surgical eye care services across more than 180 locations.

According to the company, the tool provides free access to training and mentors for eye care professionals in areas with the greatest need, and the new Cybersight mobile app expands access for eye care professionals through offline functionality.

Prevent Blindness declares September as Sports Eye Safety Month to educate the public on the risk of significant eye injuries and the need for the proper sports eye protection.

According to the university, a special antibody that is derived from llamas, called a nanobody, can stop the misfolding and the activation of Rhodopsin, a molecule whose mutations can lead to blindness.

The study from New Zealand was conducted on an otherwise healthy 28-year-old woman.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

The research by Scott N J Watamaniuk, PhD, has potential implications for patients diagnosed with strabismus.

Amber is leveraging a multi-kilobase RNA editing platform to expand the reach of treatable pathogenic variants.

Commonly used immunosuppressants used in the short term to control an ocular inflammatory disease were not associated with increased risk of developing cancer later.

European Medicines Agency issued approval for a Clinical Trial Application of its new gene therapy, VG901, which uses an adeno-associated virus vector to treat CNGA1-associated retinitis pigmentosa.

The findings of this study shed new light on processes such as learning and memory but also the development of blinding conditions.

Clinicians should be alert to the fact that while artificial intelligence (AI) is capable of generating ideas and references, it is crucial to thoroughly vet and fact-check any medical research content that AI produces.

Without treatment, severe visual impairment can occur; the first-line treatment for these cases is anti-vascular endothelial growth factor therapy (VEGF).